Adar Yaacov

7PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 26, 2026
A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer.

|Jun 04, 2026
CBFB mutations predict endocrine therapy benefit in estrogen receptor-positive breast cancer.

|Jan 09, 2026
The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.

Adar Yaacov, Roni Gillis, Jaber Salim

|Oct 20, 2022
Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver Variants.

Jakob Landau, Linoy Tsaban, Adar Yaacov

|Aug 05, 2022
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.

Renata Ferrarotto, Vasudha Mishra, Elad Herz

|Jun 21, 2022
High throughput SARS-CoV-2 variant analysis using molecular barcodes coupled with next generation sequencing.

Lyora A Cohen-Aharonov, Annie Rebibo-Sabbah, Adar Yaacov

Pageof 2

Frequent Collaborators

2 joint publications

Albert Grinshpun

1 joint publications

Dashiell J Massey

1 joint publications

Amnon Koren

1 joint publications

Sheera Adar